While targeted therapy is yielding promising results in the treatment of specific cancers, drug resistance poses a problem. We present a new mathematical framework which can be used to study the principles underlying the emergence and prevention of resistance in cancers, treated with targeted small molecule drugs. We consider a stochastic dynamical system which is based on measurable parameters, such as the rate at which resistant mutants are generated, and the turnover rate of tumor cells (we define the turnover rate as the ratio of the natural death rate and the replication rate of cancer cells in the absence of treatment). We find that resistance against nontoxic small molecule inhibitors arises mainly before the start of treatment, rather than in the course of therapy. In other words, resistant mutants pre-exist treatment, they are naturally generated during tumorigenesis.
